{"id":3427,"date":"2020-04-24T13:04:42","date_gmt":"2020-04-24T12:04:42","guid":{"rendered":"https:\/\/ceptonstrategies.com\/en\/?p=3427"},"modified":"2020-04-24T14:28:41","modified_gmt":"2020-04-24T13:28:41","slug":"cepton-inato-covid-19-clinical-trials-newsletter-4","status":"publish","type":"post","link":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/","title":{"rendered":"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4"},"content":{"rendered":"<p>COVID-19 Vaccine trials activity has been very high in recent weeks; most products are still at the preclinical stage, but there are already phase I and phase II trials ongoing, most of them from China. Regarding drug clinical trials, our update gives a good picture of today&#8217;s research activity by geographical region.<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-large wp-image-3443\" src=\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0001-1-709x1024.jpg\" alt=\"\" width=\"640\" height=\"924\" srcset=\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0001-1-709x1024.jpg 709w, https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0001-1-208x300.jpg 208w, https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0001-1-768x1109.jpg 768w, https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0001-1.jpg 1125w\" sizes=\"(max-width: 640px) 100vw, 640px\" \/><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-large wp-image-3431\" src=\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0002-709x1024.jpg\" alt=\"\" width=\"640\" height=\"924\" srcset=\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0002-709x1024.jpg 709w, https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0002-208x300.jpg 208w, https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0002-768x1109.jpg 768w, https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/CEPTON-News-COVID-N4_page-0002.jpg 1125w\" sizes=\"(max-width: 640px) 100vw, 640px\" \/><\/p>\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>COVID-19 Vaccine trials activity has been very high in recent weeks; most products are still at the preclinical stage, but there are already phase I and phase II trials ongoing, most of them from China. Regarding drug clinical trials, our update gives a good picture of today&#8217;s research activity by geographical region.<\/p>\n","protected":false},"author":4,"featured_media":3363,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[85],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CEPTON-INATO COVID-19 Clinical Trials Newsletter #4 &#8211; Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare<\/title>\n<meta name=\"description\" content=\"COVID-19 VACCINES and drug clinical trials update\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4 &#8211; Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare\" \/>\n<meta property=\"og:description\" content=\"COVID-19 VACCINES and drug clinical trials update\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-24T12:04:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-24T13:28:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3500\" \/>\n\t<meta property=\"og:image:height\" content=\"2333\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marc-Olivier B\u00e9vierre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marc-Olivier B\u00e9vierre\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\"},\"author\":{\"name\":\"Marc-Olivier B\u00e9vierre\",\"@id\":\"https:\/\/ceptonstrategies.com\/#\/schema\/person\/188c09921fb1de3e844a50cc08540bf3\"},\"headline\":\"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4\",\"datePublished\":\"2020-04-24T12:04:42+00:00\",\"dateModified\":\"2020-04-24T13:28:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\"},\"wordCount\":57,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ceptonstrategies.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg\",\"articleSection\":[\"2020\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\",\"url\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\",\"name\":\"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4 &#8211; Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare\",\"isPartOf\":{\"@id\":\"https:\/\/ceptonstrategies.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg\",\"datePublished\":\"2020-04-24T12:04:42+00:00\",\"dateModified\":\"2020-04-24T13:28:41+00:00\",\"description\":\"COVID-19 VACCINES and drug clinical trials update\",\"breadcrumb\":{\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage\",\"url\":\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg\",\"contentUrl\":\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg\",\"width\":3500,\"height\":2333},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ceptonstrategies.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ceptonstrategies.com\/#website\",\"url\":\"https:\/\/ceptonstrategies.com\/\",\"name\":\"Cepton Stategies Conseil\",\"description\":\"CEPTON is a parisian consulting firm. Our senior consultants are specialized in the pharmaceutical, medtech and healthcare industries\",\"publisher\":{\"@id\":\"https:\/\/ceptonstrategies.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ceptonstrategies.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ceptonstrategies.com\/#organization\",\"name\":\"Cepton Strategies\",\"url\":\"https:\/\/ceptonstrategies.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ceptonstrategies.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2019\/01\/LOGO_CEPTON_CMJN.jpg\",\"contentUrl\":\"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2019\/01\/LOGO_CEPTON_CMJN.jpg\",\"width\":938,\"height\":423,\"caption\":\"Cepton Strategies\"},\"image\":{\"@id\":\"https:\/\/ceptonstrategies.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/strategies-cepton\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/ceptonstrategies.com\/#\/schema\/person\/188c09921fb1de3e844a50cc08540bf3\",\"name\":\"Marc-Olivier B\u00e9vierre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ceptonstrategies.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/22d508705e6bb61bcefa8f142de4144b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/22d508705e6bb61bcefa8f142de4144b?s=96&d=mm&r=g\",\"caption\":\"Marc-Olivier B\u00e9vierre\"},\"url\":\"https:\/\/ceptonstrategies.com\/en\/author\/marc-olivier\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4 &#8211; Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare","description":"COVID-19 VACCINES and drug clinical trials update","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/","og_locale":"en_US","og_type":"article","og_title":"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4 &#8211; Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare","og_description":"COVID-19 VACCINES and drug clinical trials update","og_url":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/","og_site_name":"Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare","article_published_time":"2020-04-24T12:04:42+00:00","article_modified_time":"2020-04-24T13:28:41+00:00","og_image":[{"width":3500,"height":2333,"url":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg","type":"image\/jpeg"}],"author":"Marc-Olivier B\u00e9vierre","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marc-Olivier B\u00e9vierre"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#article","isPartOf":{"@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/"},"author":{"name":"Marc-Olivier B\u00e9vierre","@id":"https:\/\/ceptonstrategies.com\/#\/schema\/person\/188c09921fb1de3e844a50cc08540bf3"},"headline":"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4","datePublished":"2020-04-24T12:04:42+00:00","dateModified":"2020-04-24T13:28:41+00:00","mainEntityOfPage":{"@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/"},"wordCount":57,"commentCount":0,"publisher":{"@id":"https:\/\/ceptonstrategies.com\/#organization"},"image":{"@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage"},"thumbnailUrl":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg","articleSection":["2020"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/","url":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/","name":"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4 &#8211; Consulting Firm in Pharmaceutical, MedTech &amp; Healthcare","isPartOf":{"@id":"https:\/\/ceptonstrategies.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage"},"image":{"@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage"},"thumbnailUrl":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg","datePublished":"2020-04-24T12:04:42+00:00","dateModified":"2020-04-24T13:28:41+00:00","description":"COVID-19 VACCINES and drug clinical trials update","breadcrumb":{"@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#primaryimage","url":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg","contentUrl":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2020\/04\/markus-spiske-3_SvgDspSTE-unsplash.jpg","width":3500,"height":2333},{"@type":"BreadcrumbList","@id":"https:\/\/ceptonstrategies.com\/en\/cepton-inato-covid-19-clinical-trials-newsletter-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ceptonstrategies.com\/en\/"},{"@type":"ListItem","position":2,"name":"CEPTON-INATO COVID-19 Clinical Trials Newsletter #4"}]},{"@type":"WebSite","@id":"https:\/\/ceptonstrategies.com\/#website","url":"https:\/\/ceptonstrategies.com\/","name":"Cepton Stategies Conseil","description":"CEPTON is a parisian consulting firm. Our senior consultants are specialized in the pharmaceutical, medtech and healthcare industries","publisher":{"@id":"https:\/\/ceptonstrategies.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ceptonstrategies.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ceptonstrategies.com\/#organization","name":"Cepton Strategies","url":"https:\/\/ceptonstrategies.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ceptonstrategies.com\/#\/schema\/logo\/image\/","url":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2019\/01\/LOGO_CEPTON_CMJN.jpg","contentUrl":"https:\/\/ceptonstrategies.com\/wp-content\/uploads\/2019\/01\/LOGO_CEPTON_CMJN.jpg","width":938,"height":423,"caption":"Cepton Strategies"},"image":{"@id":"https:\/\/ceptonstrategies.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/strategies-cepton"]},{"@type":"Person","@id":"https:\/\/ceptonstrategies.com\/#\/schema\/person\/188c09921fb1de3e844a50cc08540bf3","name":"Marc-Olivier B\u00e9vierre","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ceptonstrategies.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/22d508705e6bb61bcefa8f142de4144b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/22d508705e6bb61bcefa8f142de4144b?s=96&d=mm&r=g","caption":"Marc-Olivier B\u00e9vierre"},"url":"https:\/\/ceptonstrategies.com\/en\/author\/marc-olivier\/"}]}},"_links":{"self":[{"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/posts\/3427"}],"collection":[{"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/comments?post=3427"}],"version-history":[{"count":4,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/posts\/3427\/revisions"}],"predecessor-version":[{"id":3445,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/posts\/3427\/revisions\/3445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/media\/3363"}],"wp:attachment":[{"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/media?parent=3427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/categories?post=3427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ceptonstrategies.com\/en\/wp-json\/wp\/v2\/tags?post=3427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}